ClinicalTrials.gg
CompletedNCT02524717Updated Feb 3, 2025

A Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Participants With Mild or Moderate Hepatic Impairment Compared With Participants With Normal Hepatic Function

A Phase 1 interventional study of JNJ-56021927 in Hepatic Impairment, sponsored by Aragon Pharmaceuticals, Inc.. Completed at 2 sites in United States. Open to male participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-03.

Sponsored by Aragon Pharmaceuticals, Inc. (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
Male
01

Study summary

The purpose of this study is to characterize the pharmacokinetics of JNJ-56021927 in participants with mild and moderate hepatic impairment.

Read the detailed description

This is an open-label (all people know the identity of the intervention), single-dose, single-center, non-randomized study of JNJ-56021927 in participants who either have hepatic impairment or qualify for the control group. The study consists of 3 Phases: Screening Phase (21 Days), open-label treatment Phase (8 Days) and follow up Phase (49 Days). The duration of participation in the study for each participant is approximately 78 Days. Primarily the pharmacokinetics of JNJ-56021927 will be measured. Participants' safety will be monitored throughout the study.

02

Conditions studied

  • Hepatic Impairment

Keywords

  • Hepatic Impairment
  • JNJ-56021927
03

In context

Lead sponsor

Aragon Pharmaceuticals, Inc. is the lead sponsor of 16 studies on the registry; none are open to participants now.

First submitted after Aragon Pharmaceuticals, Inc. became part of Johnson & Johnson.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have a clinically stable hepatic function as confirmed by the serum and transaminase levels measured during Screening and those measured within 24 hours prior to study drug administration
  • Sign an document indicating that the participant understands the purpose of and procedures required for the study and are willing to participate in the study. Participants must not have hepatic encephalopathy greater than or equal to (>=) Grade 3 where the participant lacks the capacity to provide informed consent as judged by the investigator. Mild or moderate hepatic encephalopathy that would not impede informed consent in the investigator's judgment is permitted
  • Willing and able to adhere to the prohibitions and restrictions as specified in the protocol
  • If a man is sexually active with a woman of and has not had a vasectomy, he must agree to use an adequate method as deemed appropriate by the Investigator, always use a condom during sexual intercourse, and agree to not donate sperm during the study and for 3 months after receiving the study drug
  • (BMI) between 18 and 35 kilogram (kg)/meter (m)\^2 (inclusive), and body weight not less than 50 kg
  • The participant must have a total score of 5 to 6, inclusive (mild); or 7 to 9, inclusive (moderate); the investigator will determine hepatic impairment

Exclusion criteria

Exclusion Criteria:

  • Screening thyroid-stimulating hormone (TSH) level greater than (>) (ULN), or participants with known history of thyroid disorders
  • Participant who is on thyroid replacement therapy
  • History of drug abuse according to (4th edition) (DSM-IV) criteria within 2 years before Screening or positive test result(s) for drugs of abuse (that is, opiates, barbiturates, benzodiazepines, cocaine, cannabinoids, and amphetamines) at Screening or Day -1. A positive test for participants with prescriptions for drugs that may interfere with the drug screen (that is, opiates and benzodiazepines) may be allowed
  • Known allergy to the study drug or any of the of the formulation
  • Intention to donate blood or blood products during the study or for 3 months after the administration of the study drug
  • A man who plans to father a child while enrolled in the study or for 3 months after receiving the study drug
  • Known history of seizure or condition that may predispose to seizure or on medication that lowers seizure threshold
  • History of stomach or intestinal surgery or resection that would potentially alter absorption or excretion of orally administered drugs
  • Gall bladder (example, cholecystitis and cholelithiasis) or biliary tract disease
  • renal laboratory findings including serum creatinine level greater than (>) 1.5 times ULN
  • Inability to fast for 12 hours
  • History of or current clinically significant medical illness
  • Positive test for (HIV) 1 and 2 antibodies
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    JNJ-56021927

    Participants with mild and moderate hepatic impairment and with normal hepatic function will receive JNJ-56021927 240 milligram (mg) orally once on Day 1.

    Drug: JNJ-56021927

Interventions

  • Participants will receive JNJ-56021927 240 milligram (mg) orally once on Day 1.

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration (Cmax) of JNJ-56021927

    The Cmax is the maximum observed plasma concentration of JNJ-56021927.

    Time frame: Pre-dose up to 1344 hours post-dose

  2. Maximum Plasma Concentration Corrected for Unbound Fraction (Cmax_unb) of JNJ-56021927

    The Cmax_unb is the maximum observed plasma concentration corrected for unbound fraction of JNJ-56021927.

    Time frame: Pre-dose up to 1344 hours post-dose

  3. Time to Reach the Maximum Plasma Concentration (Tmax) of JNJ-56021927

    The Tmax is the time to reach the maximum observed plasma concentration of JNJ-56021927.

    Time frame: Pre-dose up to 1344 hours post-dose

  4. Area Under the Plasma Concentration-Time Curve From 0 to 24 Hours (AUC[0-24]) Post Dose of JNJ-56021927

    The AUC(0-24hrs) is the area under the plasma concentration-time curve from 0 to 24 hours post dosing.

    Time frame: Pre-dose up to 1344 hours post-dose

  5. Area Under the Plasma Concentration-Time Curve From 0 to 168 Hours (AUC[0-168]) Post Dose of JNJ-56021927

    The AUC(0-168hrs) is the area under the plasma concentration-time curve from 0 to 168 hours post dosing.

    Time frame: Pre-dose up to 1344 hours post-dose

  6. Area Under the Plasma Concentration-Time Curve From 0 to Last Quantifiable Concentration (AUC[0-last]) Post Dose of JNJ-56021927

    The AUC(0-last) is the area under the plasma concentration-time curve from 0 to time of the last quantifiable concentration.

    Time frame: Pre-dose up to 1344 hours post-dose

  7. Area Under the Plasma Concentration-Time Curve From 0 to Last Quantifiable Concentration Corrected for Unbound Fraction (AUC[last_unb]) Post Dose of JNJ-56021927

    The AUC(last_unb) corrected for unbound fraction is the area under the plasma concentration-time curve from 0 to time of the last quantifiable concentration.

    Time frame: Pre-dose up to 1344 hours post-dose

  8. Area Under the Plasma Concentration-Time Curve From 0 to Infinite Time (AUC[0-infinity]) Post Dose of JNJ-56021927

    The AUC (0-infinity) is the area under the plasma JNJ-56021927 concentration-time curve from time 0 to infinite time, calculated as the sum of AUC (0-last) and C(last)/lambda(z), in which AUC(0-last) is area under the plasma JNJ-56021927 concentration-time curve from time zero to time of the last quantifiable concentration, C(last) is the last observed quantifiable concentration and lambda(z) is elimination rate constant.

    Time frame: Pre-dose up to 1344 hours post-dose

  9. Area Under the Plasma Concentration-Time Curve From 0 to Infinite Time Corrected for Unbound Fraction (AUC[infinity_unb]) Post Dose of JNJ-56021927

    The AUC(infinity_unb) is the area under the plasma JNJ-56021927 concentration-time curve from time 0 to infinite time corrected for unbound fraction, calculated as the sum of AUC (0-last) and C(last)/lambda(z), in which AUC(0-last) is area under the plasma JNJ-56021927 concentration-time curve from time zero to time of the last quantifiable concentration, C(last) is the last observed quantifiable concentration and lambda(z) is elimination rate constant.

    Time frame: Pre-dose up to 1344 hours post-dose

  10. Percentage of Area Under the Plasma Concentration-Time Curve Obtained by Extrapolation (%AUC[infinity,ex])

    The %AUC\[infinity,ex\] is calculated by dividing the difference of AUC(0-infinity) and AUC(0-last) by AUC(0-infinity) and then multiplying by 100, (AUC\[0-infinity\] - AUC\[0-last\])\*100/AUC\[0-infinity\].

    Time frame: Pre-dose up to 1344 hours post-dose

  11. Terminal Half-life (t[1/2]) of JNJ-56021927

    Elimination half-life associated with the terminal slope Lambda (z) of the semi logarithmic drug concentration-time curve, calculated as 0.693/Lambda (z).

    Time frame: Pre-dose up to 1344 hours post-dose

  12. Elimination Rate Constant (Lambda [z]) of JNJ-56021927

    The Lambda (z) determined by first-order rate constant associated with the terminal portion of the curve, determined as the negative slope of the terminal log-linear phase of the drug concentration-time curve.

    Time frame: Pre-dose up to 1344 hours post-dose

  13. Time of Last Measurable Plasma Concentration (Tlast) of JNJ-56021927

    Time to last measurable plasma concentration is evaluated.

    Time frame: Pre-dose up to 1344 hours post-dose

  14. Total Apparent Clearance (CL/F) of JNJ-56021927

    The CL/F is defined as Dose/AUC (0-infinity).

    Time frame: Pre-dose up to 1344 hours post-dose

  15. Apparent Volume of Distribution (Vd/F) of JNJ-56021927

    The Vd/F is defined as Dose/\[Lambda (z)\*AUC (0-infinity)\].

    Time frame: Pre-dose up to 1344 hours post-dose

  16. Metabolite to Parent Drug Ratio for Maximum Observed Plasma Concentration (MPR Cmax)

    The (MPR Cmax) is metabolite to parent drug ratio for maximum observed plasma concentration.

    Time frame: Pre-dose up to 1344 hours post-dose

  17. Metabolite to Parent Drug Ratio for Area Under the Plasma Concentration-Time Curve From Time 0 to Last Observed Quantifiable Concentration (MPR AUC[0-last])

    The MPR AUClast is metabolite to parent drug ratio for area under the plasma concentration-time curve from time 0 to last quantifiable concentration (AUC \[0-last\]).

    Time frame: Pre-dose up to 1344 hours post-dose

  18. Metabolite to Parent Drug Ratio for Area Under the Plasma Concentration-Time Curve From Time Zero to Extrapolated Infinite Time (MPR AUC [0-infinity])

    The MPR AUC \[0-infinity\] is metabolite to parent drug ratio for area under the plasma concentration-time curve from time zero to extrapolated infinite time (AUC \[0-infinity\]).

    Time frame: Pre-dose up to 1344 hours post-dose

Secondary outcomes

  1. Number of Participants with Adverse Events (AEs) and Serious AEs

    An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

    Time frame: Screening up to follow-up (56 days after dose administration)

07

Study locations

2 sites
  • Knoxville, Tennessee, United States
  • San Antonio, Texas, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2015 to primary completion in Feb 2017, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2015
First posted
Aug 17, 2015
StartActual
Aug 13, 2015
Primary completionActual
Feb 9, 2017
CompletionActual
Feb 9, 2017
Last update
Feb 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02524717
Responsible party
Sponsor
First posted
Aug 17, 2015
Start date
Aug 13, 2015
Primary completion
Feb 9, 2017
Completion
Feb 9, 2017
Last update
Feb 3, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apalutamide

Start the discussion